Next Article in Journal
Antibacterials in Aquatic Environment and Their Toxicity to Fish
Next Article in Special Issue
Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients at Risk?
Previous Article in Journal
Physicochemical Compatibility Investigation of Mesalazine and Folic Acid Using Chromatographic and Thermoanalytical Techniques
Previous Article in Special Issue
Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response

Emerging Therapeutic Modalities against COVID-19

Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA
Department of Chemistry, Wesleyan University, Middletown, CT 06459, USA
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(8), 188;
Received: 13 July 2020 / Revised: 30 July 2020 / Accepted: 4 August 2020 / Published: 8 August 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
The novel SARS-CoV-2 virus has quickly spread worldwide, bringing the whole world as well as the economy to a standstill. As the world is struggling to minimize the transmission of this devastating disease, several strategies are being actively deployed to develop therapeutic interventions. Pharmaceutical companies and academic researchers are relentlessly working to investigate experimental, repurposed or FDA-approved drugs on a compassionate basis and novel biologics for SARS-CoV-2 prophylaxis and treatment. Presently, a tremendous surge of COVID-19 clinical trials are advancing through different stages. Among currently registered clinical efforts, ~86% are centered on testing small molecules or antibodies either alone or in combination with immunomodulators. The rest ~14% of clinical efforts are aimed at evaluating vaccines and convalescent plasma-based therapies to mitigate the disease's symptoms. This review provides a comprehensive overview of current therapeutic modalities being evaluated against SARS-CoV-2 virus in clinical trials. View Full-Text
Keywords: SARS-CoV-2; coronavirus; COVID-19; remdesivir; antiviral; vaccine SARS-CoV-2; coronavirus; COVID-19; remdesivir; antiviral; vaccine
Show Figures

Graphical abstract

MDPI and ACS Style

Malik, S.; Gupta, A.; Zhong, X.; Rasmussen, T.P.; Manautou, J.E.; Bahal, R. Emerging Therapeutic Modalities against COVID-19. Pharmaceuticals 2020, 13, 188.

AMA Style

Malik S, Gupta A, Zhong X, Rasmussen TP, Manautou JE, Bahal R. Emerging Therapeutic Modalities against COVID-19. Pharmaceuticals. 2020; 13(8):188.

Chicago/Turabian Style

Malik, Shipra, Anisha Gupta, Xiaobo Zhong, Theodore P. Rasmussen, Jose E. Manautou, and Raman Bahal. 2020. "Emerging Therapeutic Modalities against COVID-19" Pharmaceuticals 13, no. 8: 188.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop